| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Biology,*
Tufts University,
Medford, and the Department of Pathology,
Tufts University, Schools of Medicine and Veterinary Medicine,
Boston, Massachusetts
Although the functional role of TRPM-2/clusterin in the prostate remains controversial, it has been postulated that transcriptional activation of the gene is an important mechanism in castration-induced prostatic involution and perhaps is a means for prostatic cells to escape apoptotic induction. In the present study, we have measured expression levels of TRPM-2/clusterin and apoptotic activities in the prostates of castrated Noble (NBL) rats and those treated with testosterone (T) and estradiol-17ß (E2) for 16 weeks. We have previously shown that the combined sex hormone treatment (T+E2) induces dysplasia, a purported preneoplastic lesion, exclusively in the dorsolateral prostates (DLPs) of all treated rats. In the present study, we demonstrate that, as expected, castration readily induced enhanced TRPM-2/clusterin expression, which was accompanied by increased apoptotic activity in the epithelia of DLP and ventral prostate (VP). The increase in TRPM-2/clusterin expression appeared earlier and was more dramatic in the VP than in the DLP. In sharp contrast, treatment of rats with T+E2 for 16 weeks induced augmentation of TRPM-2/clusterin expression selectively in the dysplastic lesions of the DLP but not in the lesion-free VP. The enhanced expression of TRPM-2/clusterin in the dysplastic epithelium was, however, not attended by an increase in apoptotic activity within the lesion. Thus, the observed up-regulation of TRPM-2/clusterin expression in the dysplastic foci of T+E2-treated rats occurred in animals whose androgen status remained normal and, despite the increased level of expression of this gene, apoptotic activity in these lesions was unchanged from basal values measured in the DLPs of untreated rats. These findings suggest that TRPM-2/clusterin expression in dysplastic lesions was no longer repressed by androgen nor was it associated with apoptosis. We propose that overexpression of the gene is likely a phenotype of neoplastic transformation. In addition, we speculate that TRPM-2/clusterin may serve as a survival factor, which could favor accumulation of transformed cells in dysplastic foci and thus promote the carcinogenic process.
This article has been cited by other articles:
 |
|
 |
|
  H. Ammar and J. L. Closset Clusterin Activates Survival through the Phosphatidylinositol 3-Kinase/Akt Pathway J. Biol. Chem., May 9, 2008; 283(19): 12851 - 12861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamanaka, M. E. Gleave, I. Hara, M. Muramaki, and H. Miyake Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model Mol. Cancer Ther., February 1, 2005; 4(2): 187 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Orlandi, S. Pucci, A. Ciucci, F. Pichiorri, A. Ferlosio, and L. G. Spagnoli Modulation of Clusterin Isoforms Is Associated With All-Trans Retinoic Acid-Induced Proliferative Arrest and Apoptosis of Intimal Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 348 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.S. Ouyang, X. Wang, D.T.W. Lee, S.W. Tsao, and Y.C. Wong Up-regulation of TRPM-2, MMP-7 and ID-1 during sex hormone-induced prostate carcinogenesis in the Noble rat Carcinogenesis, June 1, 2001; 22(6): 965 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Asamoto, N. Hokaiwado, Y.-M. Cho, S. Takahashi, Y. Ikeda, K. Imaida, and T. Shirai Prostate Carcinomas Developing in Transgenic Rats with SV40 T Antigen Expression under Probasin Promoter Control Are Strictly Androgen Dependent Cancer Res., June 1, 2001; 61(12): 4693 - 4700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Redondo, E. Villar, J. Torres-Munoz, T. Tellez, M. Morell, and C. K. Petito Overexpression of Clusterin in Human Breast Carcinoma Am. J. Pathol., August 1, 2000; 157(2): 393 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Miyake, C. Nelson, P. S. Rennie, and M. E. Gleave Acquisition of Chemoresistant Phenotype by Overexpression of the Antiapoptotic Gene Testosterone-repressed Prostate Message-2 in Prostate Cancer Xenograft Models Cancer Res., May 1, 2000; 60(9): 2547 - 2554. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Miyake, K. N. Chi, and M. E. Gleave Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both in Vitro and in Vivo Clin. Cancer Res., May 1, 2000; 6(5): 1655 - 1663. [Abstract] [Full Text]
|
|
|
|
|
|
H. Miyake, C. Nelson, P. S. Rennie, and M. E. Gleave Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer Cancer Res., January 1, 2000; 60(1): 170 - 176. [Abstract] [Full Text]
|
|
|
|
|
|
M. Cervellera, G. Raschella, G. Santilli, B. Tanno, A. Ventura, C. Mancini, C. Sevignani, B. Calabretta, and A. Sala Direct Transactivation of the Anti-apoptotic Gene Apolipoprotein J (Clusterin) by B-MYB J. Biol. Chem., July 7, 2000; 275(28): 21055 - 21060. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
